Treating patients with advanced, metastatic esophageal cancer with an immune-system boosting drug called pembrolizumab, known by its brand name Keytruda, led to regression of tumors in some patients, according to results of a phase 2 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
https://research.weill.cornell.edu/news-events-honors/immunotherapy-may-help-patients-advanced-esophageal-cancer
Immunotherapy May Help Patients with Advanced Esophageal Cancer